In vivo Grade Recombinant Anti
-mouse CD4 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: GK1.5)- ￥4000
- Syd Labs
- 美国
- PA007200.m2a
- 2026年01月12日
- ELISA, WB, Flow cytometry, IHC, ICC, animal model study
- Mouse
- Mouse
企业认证
相关产品推荐更多 >
Anti-C4d Antibody (FITC)
￥4690
In Vivo Grade Recombinant Anti-mouse PD-L1 Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa Monoclonal Antibody (Clone 10F.9G2.1)
￥1000In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG1-D265A Kappa Monoclonal Antibody (Clone 29F.1A12.1)
￥1000Tocilizumab Biosimilar, Human IL-6R Monoclonal Antibody
￥1000In Vivo Grade Recombinant Anti-HEL VHH-mIgG1 Fc Isotype Control Antibody
￥3500
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 亚型：
Mouse IgG2a Kappa
- 形态：
Liquid
- 保存条件：
Store at 2-8℃ and protected from prolonged exposure to light. Avoid freeze/thaw cycles.
- 克隆性：
Monoclonal Antibody
- 适应物种：
Mouse
- 保质期：
如果保存在2 至 8°C，自收到之日起可保存1个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。
- 库存：
3 weeks
- 供应商：
青木生物技术（武汉）有限公司
- 宿主：
Mouse
- 应用范围：
ELISA, WB, Flow cytometry, IHC, ICC, animal model study
- 浓度：
以实际发货为准
- 靶点：
CD4
- 抗体英文名：
In vivo Grade Recombinant Anti-mouse CD4 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: GK1.5)
- 抗体名：
In vivo Grade Recombinant Anti-mouse CD4 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: GK1.5)
- 规格：
5mg
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Rapid Isotyping of Mouse Monoclonal Antibodies
from serum, valence, and avidity, all depend on isotype. Isotyping is a basis for the selection of antibody purification, conjugation, fragmentation, and storage procedures, and predicts cytotoxic properties and half-life in vivo (see Note 1 ). In addition
Production of Monoclonal Antibody by DNA Immunization with Electroporation
construct was injected intramuscularly with in vivo electroporation into mice, and the specific antibody production in mice was analyzed by enzyme-linked immunosorbent assay (ELISA). Hybridomas were generated by fusing mouse splenocytes with myeloma cells
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
